Despite the challenges posed by the Covid-19 pandemic, there is a ray of hope in the realm of rare and potentially life-threatening cancer treatment. MyChild'sCancer remains steadfast in its mission to enhance the landscape of pediatric cancer treatment, empowering parents with increased access to vital knowledge and transformative second opinions that can profoundly impact their children's treatment journeys…

In light of a 20% increase in the number of families we supported, we faced challenges with our team and budget to meet the growing demand for our services. However, in 2023, we are determined to turn this situation around and support our organization's growth. Our primary objective for the year is to enhance and fortify our two new advisory committees specializing in Solid Tumors and Neuroblastoma. These esteemed and renowned expert "dream teams" will provide invaluable guidance and assistance to patients, offering second opinions and expert navigation throughout their treatment journeys. We are committed to empowering and supporting our patients with the best possible care.

As we reflect on the past year, 2023 stands as a testament to the resilience of our organization and the families we serve. In 2023, we were able to provide life-changing support to 90 children and young adults, all at no cost. This year, we reached a milestone, supporting our 1,000th family through our organization!

In 2023, we established two new advisory expert committees specializing in neuroblastoma and sarcoma, alongside our existing committee focusing on brain cancers. Now, our three expert committees cover all aspects of pediatric cancers—Brain, Soft Tissue, and Neuroblastoma.

In June 2023, a significant milestone was achieved as we hosted our inaugural seminar and conference in Israel dedicated to pediatric brain tumor experts, with a specific focus on Brain tumors.

In 2024, MyChild’sCancer experienced remarkable growth alongside profound challenges. Despite the ongoing war in Israel and its impact on resources, we expanded our programs, supported more families than ever, and remained committed to improving outcomes for children battling cancer. Key milestones included the launch of an International Tumor Board for sarcomas, impactful educational seminars, and a 20% increase in families served. With 72% of second-opinion cases leading to treatment changes or confirmation, our expert-driven support made a tangible difference. As we look to 2025, we are focused on growth, innovation, and launching new initiatives like a seminar on long-term cancer side effects. Read the full report here.